




Cell cycle profiles by flow cytometry analysis of HCT116-RIF1-mAID-GFP cells treated with different doses of ICRF-193 or camptothecin (CPT)




DNA damage markers examined in HCT116RIF1-mAID-GFP cells



ICRF-193




HCT116^{RIF1-mAID-GFP}




*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001


RIF1 localization on UFBs in HCT116-RIF1-mAID-GFP cells treated low doses of ICRF-193

Verification of RIF1 depletion with DOX and IAA treatment and BLM depletion by specific siRNA





ICRF-193 sensitivity assessed by clonogenic cell survival assay of HCT116-RIF1-mAID-GFP cells with single or double depletion of RIF1 and BLM







53BP1 nuclear bodies and micronuclei formation in HCT116-RIF1-mAID-GFP cells



Verification of RIF1 depletion with DOX and IAA treatment and PICH depletion by specific siRNA



ICRF-193 sensitivity assessed by clonogenic cell survival assay of HCT116-RIF1-mAID-GFP cells with single or double depletion of RIF1 or PICH



RIF1 inhibits the formation of 53BP1 foci and micronuclei.

Expression test by western blotting of the control cell line, HCT116RIF1-AG ~~TIR1~~.

